NASDAQ:BDSX Biodesix (BDSX) Stock Price, News & Analysis $1.19 -0.05 (-4.03%) (As of 11/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Biodesix Stock (NASDAQ:BDSX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Biodesix alerts:Sign Up Key Stats Today's Range$1.11▼$1.2750-Day Range$1.19▼$1.8052-Week Range$1.11▼$2.21Volume1.72 million shsAverage Volume181,083 shsMarket Capitalization$173.11 millionP/E RatioN/ADividend YieldN/APrice Target$3.06Consensus RatingBuy Company OverviewBiodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.Read More… New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Biodesix Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks54th Percentile Overall ScoreBDSX MarketRank™: Biodesix scored higher than 54% of companies evaluated by MarketBeat, and ranked 603rd out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBiodesix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBiodesix has only been the subject of 1 research reports in the past 90 days.Read more about Biodesix's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Biodesix are expected to grow in the coming year, from ($0.35) to ($0.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biodesix is -3.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biodesix is -3.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiodesix has a P/B Ratio of 23.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Biodesix's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.29% of the outstanding shares of Biodesix have been sold short.Short Interest Ratio / Days to CoverBiodesix has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biodesix has recently increased by 0.14%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiodesix does not currently pay a dividend.Dividend GrowthBiodesix does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.29% of the outstanding shares of Biodesix have been sold short.Short Interest Ratio / Days to CoverBiodesix has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biodesix has recently increased by 0.14%, indicating that investor sentiment is decreasing. News and Social Media0.6 / 5News SentimentN/A News SentimentBiodesix has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.Search InterestOnly 3 people have searched for BDSX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Biodesix to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Biodesix insiders have bought more of their company's stock than they have sold. Specifically, they have bought $159,500.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders69.20% of the stock of Biodesix is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 20.96% of the stock of Biodesix is held by institutions.Read more about Biodesix's insider trading history. Receive BDSX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biodesix and its competitors with MarketBeat's FREE daily newsletter. Email Address BDSX Stock News HeadlinesBiodesix, Inc. (NASDAQ:BDSX) Director Matthew Strobeck Purchases 40,000 SharesNovember 7, 2024 | insidertrades.comBiodesix, Inc. (NASDAQ:BDSX) Q3 2024 Earnings Call TranscriptNovember 4, 2024 | msn.com2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.November 21, 2024 | Darwin (Ad)Biodesix Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagNovember 4, 2024 | finance.yahoo.comBiodesix Reports Strong Q3 2024 Growth in DiagnosticsNovember 2, 2024 | markets.businessinsider.comBiodesix files to sell 62.2M shares of common stock for holdersNovember 1, 2024 | markets.businessinsider.comBiodesix: Poised for Recovery and Growth Amid Temporary SetbacksNovember 1, 2024 | markets.businessinsider.comBiodesix Announces Third Quarter 2024 Results and HighlightsNovember 1, 2024 | globenewswire.comSee More Headlines BDSX Stock Analysis - Frequently Asked Questions How have BDSX shares performed this year? Biodesix's stock was trading at $1.84 at the beginning of 2024. Since then, BDSX shares have decreased by 35.3% and is now trading at $1.19. View the best growth stocks for 2024 here. How were Biodesix's earnings last quarter? Biodesix, Inc. (NASDAQ:BDSX) announced its earnings results on Friday, November, 1st. The company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). The firm had revenue of $18.15 million for the quarter, compared to analyst estimates of $18.45 million. Biodesix had a negative trailing twelve-month return on equity of 275.79% and a negative net margin of 66.84%. When did Biodesix IPO? Biodesix (BDSX) raised $76 million in an initial public offering on Wednesday, October 28th 2020. The company issued 4,200,000 shares at $17.00-$19.00 per share. Morgan Stanley and William Blair served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers. Who are Biodesix's major shareholders? Biodesix's top institutional shareholders include Sio Capital Management LLC (2.98%), Geode Capital Management LLC (0.55%), Perkins Capital Management Inc. (0.50%) and Landscape Capital Management L.L.C. (0.10%). Insiders that own company stock include Jack W Schuler, John Patience, Scott Hutton, Robin Harper Cowie, Gary Anthony Pestano, Ryan H Siurek, Kieran O'kane, Robert William Georgantas III, Chris Vazquez and Charles M Watts. View institutional ownership trends. How do I buy shares of Biodesix? Shares of BDSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Biodesix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biodesix investors own include Broadcom (AVGO), NVIDIA (NVDA), Adobe (ADBE), Arista Networks (ANET), ServiceNow (NOW), CrowdStrike (CRWD) and Meta Platforms (META). Company Calendar Last Earnings11/01/2024Today11/20/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/07/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:BDSX CUSIPN/A CIK1439725 Webwww.biodesix.com Phone303-417-0500FaxN/AEmployees220Year FoundedN/APrice Target and Rating Average Stock Price Target$3.06 High Stock Price Target$3.50 Low Stock Price Target$2.80 Potential Upside/Downside+157.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,150,000.00 Net Margins-66.84% Pretax Margin-66.84% Return on Equity-275.79% Return on Assets-43.05% Debt Debt-to-Equity Ratio1.30 Current Ratio3.40 Quick Ratio3.40 Sales & Book Value Annual Sales$65.56 million Price / Sales2.64 Cash FlowN/A Price / Cash FlowN/A Book Value$0.05 per share Price / Book23.80Miscellaneous Outstanding Shares145,467,000Free Float44,804,000Market Cap$173.11 million OptionableOptionable Beta1.22 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:BDSX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodesix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodesix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.